STEPHEN DAVIS - 05 Apr 2022 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
CEO, Director
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
05 Apr 2022
Net transactions value
$0
Form type
4
Filing time
07 Apr 2022, 18:39:17 UTC
Previous filing
25 Feb 2022
Next filing
03 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Options (Right to Buy) Award $0 +237,931 $0.000000 237,931 05 Apr 2022 Common Stock 237,931 $25.75 Direct F1
transaction ACAD Restricted Stock Units Award $0 +69,333 $0.000000 69,333 05 Apr 2022 Common Stock 69,333 Direct F2, F3
transaction ACAD Restricted Stock Units Award $0 +277,331 $0.000000 277,331 05 Apr 2022 Common Stock 277,331 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on April 5, 2023. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.
F3 The restricted stock units vest in four equal annual installments beginning April 5, 2023.
F4 Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.